vs
雅保（ALB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
雅保的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs -29.0%，领先41.7%），雅保同比增速更快（15.9% vs 5.9%），雅保自由现金流更多（$233.1M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 2.4%）
雅保是全球知名的特种化学品企业，业务覆盖研发、生产与全球销售，下设锂、溴、催化剂三大板块。锂业务线供应碳酸锂、氢氧化锂、氯化锂等锂化合物及相关试剂，产品广泛应用于消费电子、电动汽车锂电池、高性能润滑脂、热塑性弹性体等领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ALB vs RVTY — 直观对比
营收规模更大
ALB
是对方的1.8倍
$772.1M
营收增速更快
ALB
高出10.1%
5.9%
净利率更高
RVTY
高出41.7%
-29.0%
自由现金流更多
ALB
多$71.3M
$161.8M
两年增速更快
RVTY
近两年复合增速
2.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $-414.2M | $98.4M |
| 毛利率 | 13.9% | — |
| 营业利润率 | -15.2% | 14.5% |
| 净利率 | -29.0% | 12.7% |
| 营收同比 | 15.9% | 5.9% |
| 净利润同比 | -650.1% | 3.9% |
| 每股收益（稀释后） | $-3.88 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALBRVTY
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.4B | $684.0M | ||
| Q2 24 | $1.4B | $691.7M | ||
| Q1 24 | $1.4B | $649.9M |
净利润ALBRVTY
| Q4 25 | $-414.2M | $98.4M | ||
| Q3 25 | $-160.7M | $46.7M | ||
| Q2 25 | $22.9M | $53.9M | ||
| Q1 25 | $41.3M | $42.2M | ||
| Q4 24 | $75.3M | $94.6M | ||
| Q3 24 | $-1.1B | $94.4M | ||
| Q2 24 | $-188.2M | $55.4M | ||
| Q1 24 | $2.4M | $26.0M |
毛利率ALBRVTY
| Q4 25 | 13.9% | — | ||
| Q3 25 | 9.0% | 53.6% | ||
| Q2 25 | 14.8% | 54.5% | ||
| Q1 25 | 14.5% | 56.5% | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | -7.7% | 56.3% | ||
| Q2 24 | -0.7% | 55.7% | ||
| Q1 24 | 2.9% | 54.6% |
营业利润率ALBRVTY
| Q4 25 | -15.2% | 14.5% | ||
| Q3 25 | -16.6% | 11.7% | ||
| Q2 25 | 3.6% | 12.6% | ||
| Q1 25 | 1.8% | 10.9% | ||
| Q4 24 | 0.4% | 16.3% | ||
| Q3 24 | -81.9% | 14.3% | ||
| Q2 24 | -34.4% | 12.4% | ||
| Q1 24 | -13.2% | 6.8% |
净利率ALBRVTY
| Q4 25 | -29.0% | 12.7% | ||
| Q3 25 | -12.3% | 6.7% | ||
| Q2 25 | 1.7% | 7.5% | ||
| Q1 25 | 3.8% | 6.4% | ||
| Q4 24 | 6.1% | 13.0% | ||
| Q3 24 | -78.9% | 13.8% | ||
| Q2 24 | -13.2% | 8.0% | ||
| Q1 24 | 0.2% | 4.0% |
每股收益（稀释后）ALBRVTY
| Q4 25 | $-3.88 | $0.86 | ||
| Q3 25 | $-1.72 | $0.40 | ||
| Q2 25 | $-0.16 | $0.46 | ||
| Q1 25 | $0.00 | $0.35 | ||
| Q4 24 | $0.29 | $0.77 | ||
| Q3 24 | $-9.45 | $0.77 | ||
| Q2 24 | $-1.96 | $0.45 | ||
| Q1 24 | $-0.08 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $3.2B | — |
| 股东权益账面价值 | $9.5B | $7.3B |
| 总资产 | $16.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALBRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $1.9B | $931.4M | ||
| Q2 25 | $1.8B | $991.8M | ||
| Q1 25 | $1.5B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.8B | $2.0B | ||
| Q1 24 | $2.1B | $1.7B |
总债务ALBRVTY
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.6B | — | ||
| Q2 25 | $3.6B | — | ||
| Q1 25 | $3.5B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $3.5B | — | ||
| Q1 24 | $3.5B | — |
股东权益ALBRVTY
| Q4 25 | $9.5B | $7.3B | ||
| Q3 25 | $10.0B | $7.4B | ||
| Q2 25 | $10.2B | $7.6B | ||
| Q1 25 | $10.0B | $7.6B | ||
| Q4 24 | $10.0B | $7.7B | ||
| Q3 24 | $10.2B | $7.9B | ||
| Q2 24 | $11.2B | $7.9B | ||
| Q1 24 | $11.5B | $7.8B |
总资产ALBRVTY
| Q4 25 | $16.4B | $12.2B | ||
| Q3 25 | $17.1B | $12.1B | ||
| Q2 25 | $17.3B | $12.4B | ||
| Q1 25 | $17.0B | $12.4B | ||
| Q4 24 | $16.6B | $12.4B | ||
| Q3 24 | $17.5B | $12.8B | ||
| Q2 24 | $18.4B | $13.4B | ||
| Q1 24 | $19.0B | $13.4B |
负债/权益比ALBRVTY
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.31× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $233.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 16.3% | 21.0% |
| 资本支出强度资本支出/营收 | 10.9% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $692.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ALBRVTY
| Q4 25 | $388.5M | $182.0M | ||
| Q3 25 | $355.6M | $138.5M | ||
| Q2 25 | $-7.2M | $134.3M | ||
| Q1 25 | $545.4M | $128.2M | ||
| Q4 24 | $674.0K | $174.2M | ||
| Q3 24 | $240.5M | $147.9M | ||
| Q2 24 | $362.9M | $158.6M | ||
| Q1 24 | $98.0M | $147.6M |
自由现金流ALBRVTY
| Q4 25 | $233.1M | $161.8M | ||
| Q3 25 | $223.4M | $120.0M | ||
| Q2 25 | $-126.8M | $115.5M | ||
| Q1 25 | $362.8M | $112.2M | ||
| Q4 24 | $-355.1M | $149.8M | ||
| Q3 24 | $-62.6M | $125.6M | ||
| Q2 24 | $-84.7M | $136.6M | ||
| Q1 24 | $-481.4M | $129.7M |
自由现金流率ALBRVTY
| Q4 25 | 16.3% | 21.0% | ||
| Q3 25 | 17.1% | 17.2% | ||
| Q2 25 | -9.5% | 16.0% | ||
| Q1 25 | 33.7% | 16.9% | ||
| Q4 24 | -28.8% | 20.5% | ||
| Q3 24 | -4.6% | 18.4% | ||
| Q2 24 | -5.9% | 19.7% | ||
| Q1 24 | -35.4% | 20.0% |
资本支出强度ALBRVTY
| Q4 25 | 10.9% | 2.6% | ||
| Q3 25 | 10.1% | 2.6% | ||
| Q2 25 | 9.0% | 2.6% | ||
| Q1 25 | 17.0% | 2.4% | ||
| Q4 24 | 28.9% | 3.4% | ||
| Q3 24 | 22.4% | 3.3% | ||
| Q2 24 | 31.3% | 3.2% | ||
| Q1 24 | 42.6% | 2.7% |
现金转化率ALBRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | -0.31× | 2.49× | ||
| Q1 25 | 13.19× | 3.03× | ||
| Q4 24 | 0.01× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 40.01× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALB
| Energy Storage | $759.1M | 53% |
| Specialties | $348.9M | 24% |
| Ketjen | $320.1M | 22% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
